Sun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acquisition ever by an Indian pharmaceutical company. The deal values Organon at $14 per share and gives Sun Pharma a major global expansion boost, including entry into the US women’s healthcare market and stronger presence across key international regions such as China, Europe, Korea, and Latin America.